Skip to main content
. 2021 Jul 15;43(4):1013–1023. doi: 10.1038/s41401-021-00718-0

Fig. 1. Discovery of the novel STAT3 inhibitor WZ-2-033.

Fig. 1

a STAT3 expression level in normal and gastric tumor tissues (normal, n = 12; tumor, n = 12). **P ≤ 0.01 vs normal. b IHC analysis of STAT3 expression in gastric tumor tissues and corresponding normal tissues. Scale bar = 20 μm. c Disease-free survival analysis of gastric cancer patients (n = 96) from TCGA with high or low STAT3 expression levels. d STAT3 expression levels in normal and breast tumor tissues (normal, n = 34; tumor, n = 32). **P ≤ 0.01 vs normal. e Expression of STAT3 in molecular subtypes of breast tumors. Triple-negative status: ER−/PR−/Her2−. ***P ≤ 0.001. f Disease-free survival analysis of breast cancer patients (n = 535) from TCGA with high or low STAT3 expression levels. g Chemical structure of WZ-2-033. h Molecular docking of WZ-2-033 and the STAT3 protein. The red molecule represents WZ-2-033. WZ-2-033 occupies subpockets in the SH2 domain of STAT3. i SPR analysis of the interaction between WZ-2-033 and STAT3. j Western blot (upper) and melt curve (lower) analyses of the STAT3 protein in AGS cells after treatment with WZ-2-033 (3 μM) for 1 h at the indicated CETSA temperatures.